Image Place holder

Brandon J. Manley, MD

Specialty: Urology
Program: Genitourinary Oncology

Call 1-888-MOFFITT

Call 1-888-MOFFITT

Locations: Moffitt Cancer Center

Cancer Types Treated: Adrenal Carcinoma, Bladder Cancer , Kidney (Renal Cell) Cancer , Prostate Cancer , Testicular Cancer

Dr. Manley earned his MD degree at Temple University, Philadelphia, Pennsylvania. He completed a Urologic Residency at Washington University, St. Louis, Missouri and a Urologic Oncology Fellowship at Memorial Sloan Kettering Cancer Center in New York. Dr. Manley’s clinical practice centers on malignant tumors of the prostate, kidneys, bladder and testis. Using a variety of surgical techniques, including robotic and open surgery, he supports the comprehensive treatment plans for patients with genitourinary cancers at Moffitt.

Education & Training


  • Memorial Sloan Cancer Center - Urologic Oncology


  • Washington University - Urologic

Medical School:

  • Temple University - MD
Participating Trials

Combination of Nivolumab Immunotherapy with Radiation Therapy and Androgen Deprivation Therapy in the Management of Gleason Group 5 Prostate Cancer
Condition: Genitourinary
Intervention: BMS-936558 (Nivolumab); Casodex (Bicalutamide); Lupron (leuprolide acetate); Nivolumab

QUILT-3.032: A Multicenter Clinical Trial of Intravesical Bacillus Calmette-Guerin (BCG) in Combination with ALT-803 in Patients with BCG Unresponsive High Grade Non-Muscle Invasive Bladder Cancer
Condition: Genitourinary
Intervention: ALT-803; BCG

If you believe you are eligible for one of these trials or studies, please call
813-745-6100 or toll-free 1-800-679-0775.


  • Casuscelli J, Becerra MF, Seier K, Manley BJ, Benfante N, Redzematovic A, Stief CG, Hsieh JJ, Tickoo SK, Reuter VE, Coleman JA, Russo P, Ostrovnaya I, Hakimi AA. Chromophobe Renal Cell Carcinoma: Results From a Large Single-Institution Series. Clin Genitourin Cancer. 2019 Jun;17(5):373-379.e4. Pubmedid: 31326335.
  • Manley BJ, Reznik E, Ghanaat M, Kashan M, Becerra MF, Casuscelli J, Tennenbaum D, Redzematovic A, Carlo MI, Sato Y, Arcila M, Voss MH, Feldman DR, Motzer RJ, Russo P, Coleman J, Hsieh JJ, Hakimi AA. Characterizing recurrent and lethal small renal masses in clear cell renal cell carcinoma using recurrent somatic mutations. Urol Oncol. 2019 Jan;37(1):12-17. Pubmedid: 29132830. Pmcid: PMC5984192.
  • Silagy AW, Sanchez A, Manley BJ, Bensalah K, Bex A, Karam JA, Ljungberg B, Shuch B, Hakimi AA. Harnessing the Genomic Landscape of the Small Renal Mass to Guide Clinical Management. Eur Urol Focus. 2019 Apr. Pubmedid: 31040082.
  • Peyton CC, Tang D, Reich RR, Azizi M, Chipollini J, Pow-Sang JM, Manley B, Spiess PE, Poch MA, Sexton WJ, Fishman M, Zhang J, Gilbert SM. Downstaging and Survival Outcomes Associated With Neoadjuvant Chemotherapy Regimens Among Patients Treated With Cystectomy for Muscle-Invasive Bladder Cancer. JAMA Oncol. 2018 Nov;4(11):1535-1542. Pubmedid: 30178038. Pmcid: PMC6248089.
  • Becerra MF, Reznik E, Redzematovic A, Tennenbaum DM, Kashan M, Ghanaat M, Casuscelli J, Manley B, Jonsson P, DiNatale RG, Blum KA, Durack JC, Solomon SB, Arcila ME, Bourque C, Socci N, Carlo MI, Lee CH, Voss MH, Feldman DR, Motzer RJ, Coleman JA, Russo P, Cheng EH, Hakimi AA, Hsieh JJ. Comparative Genomic Profiling of Matched Primary and Metastatic Tumors in Renal Cell Carcinoma. Eur Urol Focus. 2018 Dec;4(6):986-994. Pubmedid: 29066084. Pmcid: PMC5910293.
  • Kumar NB, Dickinson SI, Schell MJ, Manley BJ, Poch MA, Pow-Sang J. Green tea extract for prevention of prostate cancer progression in patients on active surveillance. Oncotarget. 2018 Dec;9(102):37798-37806. Pubmedid: 30701033. Pmcid: PMC6340872.
  • Kashan M, Ghanaat M, Hötker AM, Duzgol C, Sanchez A, DiNatale RG, Blum KA, Becerra M, Manley BJ, Casuscelli J, Chiok M, Coleman JA, Russo P, Tickoo SK, Akin O, Hakimi AA. Cystic Renal Cell Carcinoma: A Report on Outcomes of Surgery and Active Surveillance in Patients Retrospectively Identified on Pretreatment Imaging. J Urol. 2018 Aug;200(2):275-282. Pubmedid: 29496470. Pmcid: PMC6050111.
  • Casuscelli J, Becerra MF, Manley BJ, Zabor EC, Reznik E, Redzematovic A, Arcila ME, Tennenbaum DM, Ghanaat M, Kashan M, Stief CG, Carlo M, Voss MH, Feldman DR, Motzer RJ, Chen Y, Reuter VE, Coleman JA, Russo P, Hsieh JJ, Hakimi AA. Characterization and Impact of TERT Promoter Region Mutations on Clinical Outcome in Renal Cell Carcinoma. Eur Urol Focus. 2017 Sep;5(4):642-649. Pubmedid: 28951115. Pmcid: PMC5984188.
  • Casuscelli J, Weinhold N, Gundem G, Wang L, Zabor EC, Drill E, Wang PI, Nanjangud GJ, Redzematovic A, Nargund AM, Manley BJ, Arcila ME, Donin NM, Cheville JC, Thompson RH, Pantuck AJ, Russo P, Cheng EH, Lee W, Tickoo SK, Ostrovnaya I, Creighton CJ, Papaemmanuil E, Seshan VE, Hakimi AA, Hsieh JJ. Genomic landscape and evolution of metastatic chromophobe renal cell carcinoma. JCI Insight. 2017 Jun;2(12). Pubmedid: 28614790. Pmcid: PMC5470887.
  • Manley BJ, Tennenbaum DM, Vertosick EA, Hsieh JJ, Sjoberg DD, Assel M, Benfante NE, Strope SA, Kim E, Casuscelli J, Becerra MF, Coleman JA, Hakimi AA, Russo P. The difficulty in selecting patients for cytoreductive nephrectomy: An evaluation of previously described predictive models. Urol Oncol. 2017 Jan;35(1):35.e1-35.e5. Pubmedid: 27567689. Pmcid: PMC5154851.
  • Dong Y, Manley BJ, Becerra MF, Redzematovic A, Casuscelli J, Tennenbaum DM, Reznik E, Han S, Benfante N, Chen YB, Arcila ME, Aras O, Voss MH, Feldman DR, Motzer RJ, Fabbri N, Healey JH, Boland PJ, Chawla M, Durack JC, Lee CH, Coleman JA, Russo P, Hakimi AA, Cheng EH, Hsieh JJ. Tumor Xenografts of Human Clear Cell Renal Cell Carcinoma But Not Corresponding Cell Lines Recapitulate Clinical Response to Sunitinib: Feasibility of Using Biopsy Samples. Eur Urol Focus. 2017 Dec;3(6):590-598. Pubmedid: 28753786. Pmcid: PMC5608640.
  • Tennenbaum DM, Manley BJ, Zabor E, Becerra MF, Carlo MI, Casuscelli J, Redzematovic A, Khan N, Arcila ME, Voss MH, Feldman DR, Motzer RJ, Benfante NE, Coleman JA, Russo P, Hsieh JJ, Hakimi AA. Genomic alterations as predictors of survival among patients within a combined cohort with clear cell renal cell carcinoma undergoing cytoreductive nephrectomy. Urol Oncol. 2017 Aug;35(8):532.e7-532.e13. Pubmedid: 28408295. Pmcid: PMC5545055.
  • Hsieh JJ, Manley BJ, Khan N, Gao J, Carlo MI, Cheng EH. Overcome tumor heterogeneity-imposed therapeutic barriers through convergent genomic biomarker discovery: A braided cancer river model of kidney cancer. Semin Cell Dev Biol. 2017 Apr;64:98-106. Pubmedid: 27615548. Pmcid: PMC5522717.
  • Manley BJ, Hakimi AA. Molecular profiling of renal cell carcinoma: building a bridge toward clinical impact. Curr Opin Urol. 2016 Sep;26(5):383-387. Pubmedid: 27467134. Pmcid: PMC5032025.
  • Şenbabaoğlu Y, Gejman RS, Winer AG, Liu M, Van Allen EM, de Velasco G, Miao D, Ostrovnaya I, Drill E, Luna A, Weinhold N, Lee W, Manley BJ, Khalil DN, Kaffenberger SD, Chen Y, Danilova L, Voss MH, Coleman JA, Russo P, Reuter VE, Chan TA, Cheng EH, Scheinberg DA, Li MO, Choueiri TK, Hsieh JJ, Sander C, Hakimi AA. Tumor immune microenvironment characterization in clear cell renal cell carcinoma identifies prognostic and immunotherapeutically relevant messenger RNA signatures. Genome Biol. 2016 Nov;17(1):231. Pubmedid: 27855702. Pmcid: PMC5114739.
  • Manley B, Hakimi AA. Editorial Comment. J Urol. 2016 Nov;196(5):1370. Pubmedid: 27545335.
  • Manley BJ, Hsieh JJ. Sarcomatoid renal cell carcinoma: genomic insights from sequencing of matched sarcomatous and carcinomatous components. Transl Cancer Res. 2016 Aug;5(Suppl 2):S160-S165. Pubmedid: 29167760. Pmcid: PMC5695716.
  • Manley B, Andriole GL. Editorial comment. Urology. 2015 Feb;85(2):341-342. Pubmedid: 25623681.
  • Manley BJ, Gericke RK, Brockman JA, Robles J, Raup VT, Bhayani SB. The pitfalls of electronic health orders: development of an enhanced institutional protocol after a preventable patient death. Patient Saf Surg. 2014 Sep;8(1):39. Pubmedid: 25309624. Pmcid: PMC4193978.
  • Tomaszewski JJ, Uzzo RG, Kocher N, Li T, Manley B, Mehrazin R, Ito T, Abbosh P, Viterbo R, Chen DY, Greenberg RE, Canter D, Smaldone MC, Kutikov A. Patients with anatomically "simple" renal masses are more likely to be placed on active surveillance than those with anatomically "complex" lesions. Urol Oncol. 2014 Nov;32(8):1267-1271. Pubmedid: 24913564. Pmcid: PMC4258180.
  • Canter D, Kutikov A, Manley B, Egleston B, Simhan J, Smaldone M, Teper E, Viterbo R, Chen DY, Greenberg RE, Uzzo RG. Utility of the R.E.N.A.L. nephrometry scoring system in objectifying treatment decision-making of the enhancing renal mass. Urology. 2011 Nov;78(5):1089-1094. Pubmedid: 22054378. Pmcid: PMC3477543.
  • Kutikov A, Smaldone MC, Egleston BL, Manley BJ, Canter DJ, Simhan J, Boorjian SA, Viterbo R, Chen DY, Greenberg RE, Uzzo RG. Anatomic features of enhancing renal masses predict malignant and high-grade pathology: a preoperative nomogram using the RENAL Nephrometry score. Eur Urol. 2011 Aug;60(2):241-248. Pubmedid: 21458155. Pmcid: PMC3124570.
  • Scoll BJ, Uzzo RG, Chen DY, Boorjian SA, Kutikov A, Manley BJ, Viterbo R. Robot-assisted partial nephrectomy: a large single-institutional experience. Urology. 2010 Jun;75(6):1328-1334. Pubmedid: 20080290. Pmcid: PMC2879432.
  • Manley BJ, Brockman JA, Raup VT, Fowler KJ, Andriole GL. Prostate MRI: a national survey of Urologist's attitudes and perceptions. Int Braz J Urol. 42(3):464-471. Pubmedid: 27286108. Pmcid: PMC4920562.
  • Raup VT, Potretzke AM, Manley BJ, Brockman JA, Bhayani SB. Hemorrhagic Cystitis Requiring Bladder Irrigation is Associated with Poor Mortality in Hospitalized Stem Cell Transplant Patients. Int Braz J Urol. 41(6):1126-1131. Pubmedid: 26742970. Pmcid: PMC4756938.
  • Manley BJ, Kim EH, Vetter JM, Potretzke AM, Strope SA. Validation of preoperative variables and stratification of patients to help predict benefit of cytoreductive nephrectomy in the targeted therapy ERA. Int Braz J Urol. 43(3):432-439. Pubmedid: 28128914. Pmcid: PMC5462133.